On Tuesday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Finjan Holdings, Inc. (NASDAQ:FNJN), Solar3D, Inc. (NASDAQ:SLTD), IsoRay, Inc. (NYSEMKT:ISR), OvaScience, Inc. (NASDAQ:OVAS)
Finjan Holdings, Inc. (NASDAQ:FNJN), with shares gained 17.07%, closed at $2.40.
Solar3D, Inc. (NASDAQ:SLTD), with shares jumped 15.19%, settled at $4.17.
IsoRay, Inc. (NYSEMKT:ISR), with shares climbed 12.25%, and closed at $1.74.
OvaScience, Inc. (NASDAQ:OVAS), surged 12.17%, and closed at $53.46, hitting new 52-week high of $55.63.
Latest NEWS regarding these Stocks are depicted underneath:
Finjan Holdings, Inc. (NASDAQ:FNJN)
Formerly on March 10, Finjan Holdings, Inc. (FNJN), provided shareholders update.
Key Milestones:
- On March 3, 2015 the U.S. District Court for Northern District of California adopted all of Finjan’s claim constructions in the case verse Sophos during the Markman hearing.
- Finjan recently moved its headquarters to new offices in Silicon Valley, closing its offices in New York thus bringing all corporate assets collectively to California.
- CEO Phil Hartstein take partd as a delegation of CEOs to President Obama’s Stanford Summit on Cyber Security and Consumer Protection.
- Successfully sold its wholly-owned organic fertilizer partner, for $675,000 in cash to focus exclusively on its web and network security technology line of business. Based on this Finjan will advance growth plans to attain quality, synergistic technology companies with complementary IP portfolios.
- Since successfully licensing its cybersecurity technologies to a number of major industry players that has returned, to date, over $150 million, Finjan declared its first patent licensing deal as a public corporation for $8 million.
Administration will attend the USPTO Quality Summit Program from March 25-26 in Alexandria, VA.
Finjan Holdings, Inc., a technology corporation, focuses on the development of new technologies and licensing of its intellectual property. The corporation owns a portfolio of patents related to software that proactively detect malicious code and thereby protects end-users from identity and data theft, spyware, malware, phishing, trojans, and other online threats.
Solar3D, Inc. (NASDAQ:SLTD)
Formerly on March 19, Solar3D, Inc. (SLTD), declared that its MD Energy partner has secured a $2.4 million contract from the Rancho Mirage Public Library to install a complex solar system designed to protect against rising electric utility costs.
Located in Southern California, the Rancho Mirage Public Library sought to implement a solar program that would reduce dependency on local utility providers while ultimately resulting in long-term cost savings. In the near term, MD Energy anticipates to finalize the design for the project, complete the construction documents and undertake the permitting phase of construction.
Solar3D, Inc. develops and markets three-dimensional version of solar cell technology to enhance the conversion of sunlight into electricity in the United States. It also designs, installs, and manages solar systems for commercial, agricultural, and residential customers; and designs, finances, and installs systems ranging in size from 2 kilowatt for residential loads to multi megawatt systems for larger commercial projects.
IsoRay, Inc. (NYSEMKT:ISR)
IsoRay, Inc. (ISR), declared it will host a dinner presentation on March 28 by Dr. Jonathan Feddock describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131. IsoRay will have booth #516 at the 2015 Annual Meeting of the Society of Gynecologic Oncology (SGO). The annual meeting will take place March 28-31, 2015 at the Chicago Hilton in Chicago, Illinois.
According to IsoRay CEO Dwight Babcock, “With the recently published and peer-reviewed results for gynecologic cancer, we are seeing a growing level of interest by gynecologic oncologists due to the noteworthy results being achieved using Cesium-131. Cesium-131’s stated success in treating primary in addition to recurrent gynecologic cancers that have not responded to other treatments continues to get the attention of physicians who need new treatment options.”
IsoRay is very happy to have Dr. Feddock, an industry leader who practices at University of Kentucky HealthCare, talk about the success, methods and new approaches being implemented in brachytherapy.
IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The corporation produces Proxcelan Cesium
OvaScience, Inc. (NASDAQ:OVAS)
OvaScience, Inc. (OVAS), declared that Michelle Dipp, M.D., Ph.D., was elected to join the World Economic Forum’s Young Global Leaders (YGL). Dr. Dipp’s commitment to the global community – particularly the fertility community – in addition to her leadership and the contributions she has made to the healthcare industry throughout her career, led to her selection as one of the world’s most outstanding next-generation leaders.
Dr. Dipp joins other notable YGLs, counting: Elon Musk, Co-Founder and Chief Executive Officer of Tesla; Marissa Mayer, Chief Executive Officer of Yahoo; Mark Zuckerberg, Founder and Chief Executive Officer of Facebook; David Rhodes, President of CBS News; Valerie Casey, Chief Product Officer, Global Innovation Center at Samsung; and Toru Hashimoto, Mayor of Osaka City, Japan.
OvaScience, Inc., a life science corporation, engages in the discovery, development, and commercialization of new treatments for infertility. The corporation’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
